SANDOZ CIPROFLOXACIN 0.3 %
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 % · DIN 02387131 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ CIPROFLOXACIN?
SANDOZ CIPROFLOXACIN 0.3 % contains CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 %. It is listed in the Health Canada Drug Product Database under DIN 02387131, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 03-Jul-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ CIPROFLOXACIN used for?
Sandoz Ciprofloxacin (ciprofloxacin ophthalmic solution) is indicated for the treatment of the following infections of the eye and its adnexae when caused by susceptible strains of the designated bacteria. Corneal Ulcers: Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae. Conjunctivitis: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus influenzae.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02387131 |
|---|---|
| Brand name | SANDOZ CIPROFLOXACIN |
| Generic / active ingredient | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 % |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 0.3 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01AE03 CIPROFLOXACIN |
| AHFS class | 52:04.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Jul-2012 |
| Original market date | 2012-07-03 00:00:00 |
How is it administered?
Conjunctivitis: 1-2 drops every 2h (2 days), then every 4h (5 days). Corneal Ulcer: 2 drops every 15-30 min (Day 1), hourly (Day 2), then every 4h (Days 3-14).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store in the carton at room temperature (2 °C – 30 °C). Keep out of reach and sight of children.
How is it supplied?
5mL plastic Droptainer dispensers
Contraindications
Hypersensitivity to ciprofloxacin, other quinolones (including nalidixic acid), or any ingredient in the formulation/container.
Warnings and precautions
Not for injection. Discontinue at first sign of hypersensitivity or tendon inflammation. May cause temporary blurred vision. Avoid contact lens wear during treatment.
Is CIPROFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01AE03 CIPROFLOXACIN. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CILOXAN | 0.3 % | OINTMENT | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02200864 |
| APO-CIPROFLOX | 0.3 % | SOLUTION | APOTEX INC | DORMANT | DIN 02263130 |
| NU-CIPROFLOX | 0.3 % | SOLUTION | NU-PHARM INC | CANCELLED (UNRETURNED ANNUAL) | DIN 02333228 |
| PMS-CIPROFLOXACIN 0.3% | 0.3 % | SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02253933 |
Who else supplies CIPROFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CIPROFLOXACIN appears in 449 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.